In the former, fusion oncoproteins function as aberrant transcription factors, disrupting normal gene regulatory networks that govern proliferation and differentiation, whereas in the latter, chaotic genomic rearrangements (including chromothripsis) and recurrent inactivation of tumor suppressors like TP53 and RB1 promote genomic instability and therapeutic resistance [155,156]. This evidence concerns the gene TP53 and neoplasm.